# A Study of IBR854 Combined With Pazopanib Versus Pazopanib in Advanced Renal Cell Carcinoma

> **NCT07087158** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Imbioray (Hangzhou) Biomedicine Co., Ltd.** · enrollment: 30 (estimated)

## Conditions studied

- Renal Cell Carcinoma (RCC)

## Interventions

- **DRUG:** IBR854
- **DRUG:** Pazopanib

## Key facts

- **NCT ID:** NCT07087158
- **Lead sponsor:** Imbioray (Hangzhou) Biomedicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-08-10
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-07-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07087158

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07087158, "A Study of IBR854 Combined With Pazopanib Versus Pazopanib in Advanced Renal Cell Carcinoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07087158. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*